STOCKER1970 / SHUTTERSTOCK.COM
This year’s Life Sciences Law Forum is taking place on June 25 in London. LSIPR caught up with the conference’s chair James Horgan, of Merck Sharp & Dohme, and GlaxoSmithKline counsel Anthony Kenny to find out what’s keeping them busy and what they’ll discuss on the day.
James Horgan, legal director of European patents at Merck Sharp & Dohme (MSD)
What is your day-to-day role at MSD, and what projects are you working on at the moment?
The team of patent attorneys here is responsible for prosecuting the vast majority of MSD’s patent applications in Europe, and that includes defending oppositions against our own patents and filing oppositions against third parties. We also file large numbers of supplementary protection certificates (SPCs), and there will be a lot of those in a year when there are a number of new product launches.
On top of this, we get involved in some of MSD’s patent litigation in the UK and Europe, as well as supporting business needs with due diligence and general patent questions.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
MSD, Merck Sharp & Dohme, SPCs, patent, patent application, Life Sciences Law Forum